moomoo ID:NaN
Log Out
  • 中文繁体
  • 中文简体

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > IMVT Immunovant > Company Executives
IMVT Immunovant
Post Mkt Price
NamePositionSalaryService DateEducationAgeGenderUpdated
Dr. Peter Salzmann, M.B.A.Director and Chief Executive Officer5.87M----54male06/30/2022
Mr. Mark S. LevineChief Legal Officer and Corporate Secretary------49male06/30/2022
Ms. Julia G. ButchkoChief Development and Technology Officer7.84M----51female06/30/2022
Ms. Pamela Yanchik Connealy, M.B.A.Chief Financial Officer and Chief Accounting Officer5.60M----59female08/12/2021
Mr. William L. MaciasChief Medical Officer6.82M----64male06/30/2022
Ms. Eva Renee BarnettChief Financial and Accounting Officer4.43M----42female06/30/2022
Dr. Frank M. Torti, M.D.Executive Chairman of the Board2.74M----43male06/30/2022
Mr. Andrew J. FromkinDirector650.06K----56male06/30/2022
Dr. Eric VenkerDirector------35male06/30/2022
Mr. George V. MigauskyIndependent Director702.60K----67male06/30/2022
Dr. Atul Pande, M.D.Independent Director637.92K----67male06/30/2022
Mr. Douglas J. HughesIndependent Director701.62K----60male06/30/2022
Company Overview More
Immunovant, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.
CEO: Dr. Peter Salzmann, M.B.A.
Market: NASDAQ
Hot List
SymbolLatest price%Chg